iScience (Apr 2021)

Evidence for tmTNF reverse signaling in vivo: Implications for an arginase-1-mediated therapeutic effect of TNF inhibitors during inflammation

  • Katy Diallo,
  • Numa Simons,
  • Souraya Sayegh,
  • Michel Baron,
  • Yannick Degboé,
  • Jean-Frédéric Boyer,
  • Andrey Kruglov,
  • Sergei Nedospasov,
  • Julien Novarino,
  • Meryem Aloulou,
  • Nicolas Fazilleau,
  • Arnaud Constantin,
  • Alain Cantagrel,
  • Jean-Luc Davignon,
  • Benjamin Rauwel

Journal volume & issue
Vol. 24, no. 4
p. 102331

Abstract

Read online

Summary: In order to ascertain the significance of transmembrane tumor necrosis factor (tmTNF) reverse signaling in vivo, we generated a triple transgenic mouse model (3TG, TNFR1−/−, TNFR2−/−, and tmTNFKI/KI) in which all canonical tumor necrosis factor (TNF) signaling was abolished. In bone-marrow-derived macrophages harvested from these mice, various anti-TNF biologics induced the expression of genes characteristic of alternative macrophages and also inhibited the expression of pro-inflammatory cytokines mainly through the upregulation of arginase-1. Injections of TNF inhibitors during arthritis increased pro-resolutive markers in bone marrow precursors and joint cells leading to a decrease in arthritis score. These results demonstrate that the binding of anti-TNF biologics to tmTNF results in decreased arthritis severity. Collectively, our data provide evidence for the significance of tmTNF reverse signaling in the modulation of arthritis. They suggest a complementary interpretation of anti-TNF biologics effects in the treatment of inflammatory diseases and pave the way to studies focused on new arginase-1-dependent therapeutic targets.

Keywords